title: Demonstration of antibodies to the chitin-binding mistletoe lectin (cbML) in tumor patients before and during therapy with an aqueous mistletoe extract.
abstract: Mistletoe extracts exert immunomodulatory properties in vivo and in vitro, and these effects have been related mainly to mistletoe lectin 1 (ML-1). Recently, a new chitin-binding mistletoe lectin (cbML) has been isolated and structurally characterized in these extracts. Aim of the present study was, therefore, to evaluate whether this cbML also affects immunocompetent cells and can for instance activate B-cells to produce anti-cbML-specific antibodies. Sera from patients with different tumors who were treated with the mistletoe extract ABNOBAviscum Mali (AM) 4 for at least 18 weeks were analysed before therapy and after 3, 6, 9, 12, 18, and 24 weeks. Sera were tested by ELISA against ML-1, -3, and cbML, isolated from a single mistletoe plant collected from an apple tree (Malus domestica). Eight of the 26 patients (31%) had IgG anti-cbML antibodies already before therapy, while only four had anti-ML-1 and -3 antibodies. Of the 18 anti-cbML negative patients before therapy 54% developed these antibodies during therapy, and there was a significant increase in anti-cbML antibody titers. In contrast, anti-ML-1 or -3-antibodies developed in almost 100% of the 25 patients being negative before therapy. These data indicate that cbML can induce immunological responses in patients treated with mistletoe extracts, although it seems to have lower antigenicity. Interestingly, anti-cbML antibodies can be observed in a low incidence also in individuals, not having yet received mistletoe therapy.
authors.affiliation: Department of Internal Medicine II, University of Tübingen, Otfried-Müller-Strasse 10, D-72076 Tübingen, Germany. reinhild.klein@med.uni-tuebingen.de
authors.forename: R
authors.initials: R
authors.lastname: Klein
authors.forename: M
authors.initials: M
authors.lastname: Franz
authors.forename: R
authors.initials: R
authors.lastname: Wacker
authors.forename: K
authors.initials: K
authors.lastname: Classen
authors.forename: R
authors.initials: R
authors.lastname: Scheer
authors.forename: H B
authors.initials: HB
authors.lastname: Von Laue
authors.forename: S
authors.initials: S
authors.lastname: Stoeva
authors.forename: W
authors.initials: W
authors.lastname: Voelter
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000906:Antibodies / Q000032:analysis / Q000097:blood; D001943:Breast Neoplasms / Q000188:drug therapy / Q000276:immunology; D002280:Basal Cell Carcinoma / Q000188:drug therapy / Q000276:immunology; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000276:immunology; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014784:Mistletoe; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D010936:Plant Extracts / Q000627:therapeutic use*; D037121:Plant Lectins / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D000906:Antibodies; D010936:Plant Extracts; D037121:Plant Lectins